The Lancet published peer-reviewed, interim results of the Oxford COVID-19 vaccine (AZD1222) studies find that the vaccine protects against symptomatic disease in 70 percent of cases, with vaccine efficacy (VE) of 62 percent for those given 2 full doses.
Additionally, The Lancet disclosed on December 8, 2020, the VE was reported at 90 percent in those participants given a half, then a full dose (both trial arms pre-specified in the pooled analysis).
Read More
